EP. 1: Significance of KEYNOTE-189 in NSCLC
Watch
EP. 2: Bevacizumab in NSCLC
EP. 3: Ramucirumab in Relapsed/Refractory NSCLC
EP. 4: The Phase 3 REVEL Trial in NSCLC
EP. 5: VEGF Inhibition in NSCLC
EP. 6: Immunotherapy and <i>VEGF</i>-Targeted Therapy in NSCLC
EP. 7: Future Use of Antiangiogenic Agents in NSCLC
EP. 8: Evidence for Immunotherapy in Frontline NSCLC
EP. 9: Considerations for Antiangiogenic Therapy in NSCLC
EP. 10: Key Points From the REVEL Trial in NSCLC
EP. 11: Breakthroughs in Treating NSCLC
EP. 12: Antiangiogenic Therapy in NSCLC
EP. 13: Pembrolizumab in First-Line Nonsquamous NSCLC
EP. 14: Rationale for Ramucirumab in NSCLC
EP. 15: Necitumumab in Squamous NSCLC
EP. 16: Antiangiogenic Therapy in NSCLC: Addressing the Unknown
EP. 17: Using Antiangiogenic Therapy in NSCLC in the Future
EP. 18: Sequencing Therapy in NSCLC